Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial(§)

por Gallant, Joel, Moyle, Graeme, Berenguer, Juan, Shalit, Peter, Cao, Huyen, Liu, Ya-Pei, Myers, Joel, Rosenblatt, Lisa, Yang, Lingfeng, Szwarcberg, Javier
Publicado 2017

Erratum to: Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

por Andreatta, Kristen, Willkom, Madeleine, Martin, Ross, Chang, Silvia, Wei, Lilian, Liu, Hui, Liu, Ya-Pei, Graham, Hiba, Quirk, Erin, Martin, Hal, White, Kirsten L
Publicado 2019

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

por Andreatta, Kristen, Willkom, Madeleine, Martin, Ross, Chang, Silvia, Wei, Lilian, Liu, Hui, Liu, Ya-Pei, Graham, Hiba, Quirk, Erin, Martin, Hal, White, Kirsten L
Publicado 2019

Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologi...

por Daar, Eric, DeJesus, Edwin, Ruane, Peter, Crofoot, Gordon, Oguchi, Godson, Creticos, Catherine, Rockstroh, Jurgen K, Molina, Jean-Michel, Koenig, Ellen, Liu, Ya-Pei, Andreatta, Kristen, Graham, Hiba, Cheng, Andrew, Martin, Hal, Quirk, Erin
Publicado 2017

318. Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) in Hispanic/Latinx and Black Participants: Efficacy, Bone and Renal Safety Results from a Pooled Analysis o...

por DeJesus, Edwin, Federico Andrade Villanueva, Jaime, Ramon Arribas Lopez, Jose, Brinson, Cynthia, Crofoot, Gordon, Daar, Eric S, Koenig, Ellen, Podzamczer, Daniel, Ramgopal, Moti, Santana, Jorge, Santiago, Lizette, Tebas, Pablo, Zorrilla, Carmen, Guo, Susan, Liu, Ya-Pei, Zhong, Lijie, Brainard, Diana M, Carter, Christoph C, Temme, Lauren, Das, Moupali
Publicado 2019